Form 144 Denali Therapeutics Inc. Filed by: SATO VICKI L
Denali Therapeutics Inc. (DNLI)
Last denali therapeutics inc. earnings: 8/6 04:30 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.denalitherapeutics.com
Company Research
Source: SEC EDGAR
Impact Snapshot
Event Time:
DNLI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DNLI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DNLI alerts
High impacting Denali Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
DNLI
News
- Strength Seen in Denali Therapeutics (DNLI): Can Its 10.1% Jump Turn into More Strength? [Yahoo! Finance]Yahoo! Finance
- Blood Brain Barrier Market Assessment 2024-2035, Distribution by Type of Molecule, Route of Administration, Target Disease Indication, Therapeutic Area and Key Geographical Regions [Yahoo! Finance]Yahoo! Finance
- Denali Therapeutics Inc. (NASDAQ: DNLI) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $35.00 price target on the stock.MarketBeat
- Denali Plans to File for Accelerated Approval of Hunter Syndrome Drug Wed, Sep 4, 2024, 5:37 PM GMT+2 4 min read 0 In this article: Denali's Plans for Tividenofusp Alfa Denali Presents New Data on Tividenofusp Alfa Our Take DNLI's Rank and Stocks to ConAcquire Media Monitor
- Denali Therapeutics Inc. (NASDAQ: DNLI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $90.00 price target on the stock.MarketBeat
DNLI
Earnings
- 2/27/24 - Miss
DNLI
Sec Filings
- 10/2/24 - Form 4
- 9/30/24 - Form 144
- 9/16/24 - Form 4
- DNLI's page on the SEC website